227 related articles for article (PubMed ID: 37338403)
1. A Selective Culture Medium for Screening Cefiderocol Resistance in
Ibrahim A; Bouvier M; Sadek M; Decousser JW; Poirel L; Nordmann P
J Clin Microbiol; 2023 Jul; 61(7):e0188322. PubMed ID: 37338403
[TBL] [Abstract][Full Text] [Related]
2.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
3. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
4. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany.
Kresken M; Korte-Berwanger M; Gatermann SG; Pfeifer Y; Pfennigwerth N; Seifert H; Werner G
Int J Antimicrob Agents; 2020 Oct; 56(4):106128. PubMed ID: 32758648
[TBL] [Abstract][Full Text] [Related]
6.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
7. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
[TBL] [Abstract][Full Text] [Related]
8. Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii.
Raro OHF; Bouvier M; Kerbol A; Decousser JW; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2023 Dec; 42(12):1511-1518. PubMed ID: 37910268
[TBL] [Abstract][Full Text] [Related]
9.
Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
[TBL] [Abstract][Full Text] [Related]
11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
12.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
[TBL] [Abstract][Full Text] [Related]
14. New Perspectives on Antimicrobial Agents: Cefiderocol.
McCreary EK; Heil EL; Tamma PD
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner PJ; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
19. Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Poirel L; Sadek M; Nordmann P
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0087721. PubMed ID: 34252309
[TBL] [Abstract][Full Text] [Related]
20. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]